Charles A Galea
Dr Charles Galea trained in the USA at the University of Utah and St. Jude Children’s Research Hospital where he extended his expertise in protein structure/function. At St. Jude he performed the first large-scale proteomics analysis of mammalian intrinsically disordered proteins. He also solved the structure of a human tumor suppressor protein p53 mutant involved in the development of adrenocortical carcinomas (featured on the cover of Protein Science). In addition to this, he showed that the intrinsic flexibility of the cell cycle regulatory protein p27 provides a molecular basis for its regulated degradation during cell division (highlighted in Nat Chem Biol)
In 2008 Dr Galea returned to Australia and joined Professor Ray Norton’s group at the Walter and Eliza Hall Institute (WEHI) (moved to the Monash Institute of Pharmaceutical Sciences (MIPS) in 2010) where his research focused on using NMR spectroscopy and other biophysical techniques to characterize peptide toxins and disease-associated human proteins. He is currently part of an international collaboration aiming to discover novel peptide toxins for the treatment of multiple sclerosis.
Dr Galea recently joined Professor Jian Li and Dr Tony Velkov’s group in Drug Delivery, Disposition and Dynamics at MIPS. His research focuses on understanding the mechanism of action of polymyxin, one of the few antibiotics currently available and still capable of successfully fighting multi-drug resistant bacteria